Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue. Researchers ...

Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), who are also part of the ...

Oral NMDA receptor antagonist gets an expanded indication ...

Axsome Therapeutics recently held a special call to discuss the past approval of AUVELITY, a therapy targeting NMDA and sigma-1 receptors, for treating agitation associated with dementia due to ...

Auvelity targets the NMDA and sigma-1 receptors, providing the first non-antipsychotic treatment option for Alzheimer’s patients with agitation.

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

A molecular mechanism that significantly contributes to the progression of Alzheimer's disease has been discovered by a research team led by neurobiologist Prof. Dr. Hilmar Bading of Heidelberg ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

A molecular mechanism that significantly contributes to the progression of Alzheimer’s disease has been discovered by a research team led by neurobiologist Prof. Dr Hilmar Bading of Heidelberg ...

A variety of Alzheimer’s medications can help manage different symptoms and improve quality of life as the disease progresses. Alzheimer’s medications help manage symptoms by improving memory, ...